MCID: HMN014
MIFTS: 56

Human Immunodeficiency Virus Infectious Disease

Categories: Immune diseases, Infectious diseases

Aliases & Classifications for Human Immunodeficiency Virus Infectious Disease

MalaCards integrated aliases for Human Immunodeficiency Virus Infectious Disease:

Name: Human Immunodeficiency Virus Infectious Disease 12 15
Hiv Infections 15

Classifications:



External Ids:

Disease Ontology 12 DOID:526
ICD9CM 35 042 042-042.99
MeSH 44 D015658
NCIt 50 C3108
SNOMED-CT 68 86406008
ICD10 33 B20 B20-B20
UMLS 72 C0019693

Summaries for Human Immunodeficiency Virus Infectious Disease

Disease Ontology : 12 A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has material basis in Human immunodeficiency virus 1 or has material basis in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.

MalaCards based summary : Human Immunodeficiency Virus Infectious Disease, also known as hiv infections, is related to aids dementia complex and leishmaniasis. An important gene associated with Human Immunodeficiency Virus Infectious Disease is CD4 (CD4 Molecule), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lercanidipine and Candesartan cilexetil have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and liver, and related phenotypes are cellular and hematopoietic system

Related Diseases for Human Immunodeficiency Virus Infectious Disease

Diseases related to Human Immunodeficiency Virus Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1793)
# Related Disease Score Top Affiliating Genes
1 aids dementia complex 33.2 TNF ITIH4 CXCR4 CXCL12 B2M
2 leishmaniasis 32.2 TNF IL10 IFNG
3 toxoplasmosis 32.2 TNF IL10 IFNG CCR5
4 cytomegalovirus retinitis 32.1 TNF IFNG CCR5
5 herpes zoster 32.1 IL2 IL10 IFNG
6 chlamydia 31.9 TNF IL10 IFNG
7 visceral leishmaniasis 31.9 TNF IL2 IL10 IFNG
8 pneumonia 31.9 TNF IL10 CCL5 CCL3
9 hepatitis a 31.9 TNF IL10 IFNG
10 lymphopenia 31.8 IL7R IL7 IL2 IFNG
11 mycobacterium tuberculosis 1 31.8 TNF IL10 IFNG CD209
12 uveitis 31.7 TNF IL10 IFNG
13 cytomegalovirus infection 31.7 TNF CCL5 CCL3 B2M
14 erythema multiforme 31.7 TNF IL2 IFNG
15 lung disease 31.7 TNF IL10 CCL5 CCL3
16 measles 31.7 IL2 IFNG IFNA1 CD209
17 tetanus 31.7 IL2 IL10 IFNG
18 encephalitis 31.7 ITIH4 ERVW-1 CD209 CCR5 CCL5
19 lymphoma, non-hodgkin, familial 31.7 IL2 CXCR4 CXCL12 CD38 B2M
20 mumps 31.6 TNF IL2 IFNG
21 lymphadenitis 31.6 TNF IL10 IFNG CD209
22 meningitis 31.6 TNF IL10 IFNG CCL4 CCL3
23 periodontitis 31.6 TNF IL10 IFNG
24 central nervous system lymphoma 31.6 IL2 IL10 CXCL12
25 leprosy 3 31.6 TNF IL2 IL10 IFNG
26 pulmonary tuberculosis 31.5 TNF IL2 IL10 IFNG CCL4 CCL3
27 aseptic meningitis 31.5 TNF IL10 IFNG
28 severe combined immunodeficiency 31.5 IL7R IL7 IL2 IFNG
29 aspergillosis 31.4 TNF IL10 IFNG CD209
30 poliomyelitis 31.4 TNF IL10 IFNG
31 skin disease 31.4 TNF IL10 IFNG B2M
32 stevens-johnson syndrome/toxic epidermal necrolysis 31.4 IL2 IFNG CXCR4 CCL5
33 cutaneous leishmaniasis 31.4 TNF IL10 IFNG
34 autoimmune disease 31.4 TNF IL2 IL10 IFNG IFNA1
35 acquired immunodeficiency syndrome 31.4 TNF ITIH4 IL2 IL10 IFNG IFNA1
36 neuritis 31.4 TNF IFNG CCL5
37 peritonitis 31.4 TNF IL10 B2M
38 sarcoidosis 1 31.4 TNF IL2 IFNG CCL3
39 osteomyelitis 31.4 TNF IL10 IFNG
40 colitis 31.3 TNF IL2 IL10 IFNG
41 mucocutaneous leishmaniasis 31.3 TNF IL10 CCR5
42 bone disease 31.3 TNF CCL4 CCL3 B2M
43 gastroenteritis 31.3 TNF IL10 IFNA1
44 toxic shock syndrome 31.3 TNF IL2 IL10 IFNG
45 pleural tuberculosis 31.2 TNF IFNG B2M
46 reactive arthritis 31.2 TNF IL10 IFNG
47 bronchiolitis obliterans 31.1 TNF IL10 IFNG
48 pleurisy 31.1 TNF IL2 IFNG
49 ulcerative colitis 31.1 TNF IL2 IL10 IFNG
50 spondyloarthropathy 31.1 TNF IL10 IFNG

Graphical network of the top 20 diseases related to Human Immunodeficiency Virus Infectious Disease:



Diseases related to Human Immunodeficiency Virus Infectious Disease

Symptoms & Phenotypes for Human Immunodeficiency Virus Infectious Disease

MGI Mouse Phenotypes related to Human Immunodeficiency Virus Infectious Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.25 B2M CCR5 CD28 CD38 CD4 CXCL12
2 hematopoietic system MP:0005397 10.17 B2M CCL5 CCR5 CD28 CD38 CD4
3 endocrine/exocrine gland MP:0005379 10.11 B2M CD28 CD38 CD4 CXCR4 IFNG
4 immune system MP:0005387 10.1 B2M CCL5 CCR5 CD28 CD38 CD4
5 digestive/alimentary MP:0005381 10.06 B2M CCR5 CD28 CD4 CXCR4 IFNG
6 liver/biliary system MP:0005370 9.76 B2M CCR5 CXCL12 IFNG IL10 IL2
7 neoplasm MP:0002006 9.65 B2M CCR5 CD28 CXCR4 IFNG IL10
8 no phenotypic analysis MP:0003012 9.17 CD4 CXCL12 IFNG IL10 IL2 IL7

Drugs & Therapeutics for Human Immunodeficiency Virus Infectious Disease

Drugs for Human Immunodeficiency Virus Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 867)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
2
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
3
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
4
Tipranavir Approved, Investigational Phase 4 174484-41-4 65027
5
Lopinavir Approved Phase 4 192725-17-0 92727
6
Saquinavir Approved, Investigational Phase 4 127779-20-8 60787
7
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
8
Amprenavir Approved, Investigational Phase 4 161814-49-9 65016
9
Didanosine Approved Phase 4 69655-05-6 50599
10
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
11
Indinavir Approved Phase 4 150378-17-9 5362440
12
Megestrol acetate Approved, Investigational, Vet_approved Phase 4 595-33-5 11683
13
Zalcitabine Approved, Investigational Phase 4 7481-89-2 24066
14
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
15
Zinc Approved, Investigational Phase 4 7440-66-6 32051
16
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
17
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
18
leucovorin Approved Phase 4 58-05-9 143 6006
19
Proguanil Approved Phase 4 500-92-5 4923
20
Atovaquone Approved Phase 4 95233-18-4 74989
21
Echinacea Approved, Experimental Phase 4
22
Fosamprenavir Approved Phase 4 226700-79-4 131536
23
Acyclovir Approved Phase 4 59277-89-3 2022
24
Pyrazinamide Approved, Investigational Phase 4 98-96-4 1046
25
Sulfamethoxazole Approved Phase 4 723-46-6 5329
26
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
27
Famotidine Approved Phase 4 76824-35-6 3325
28
Temazepam Approved, Investigational Phase 4 846-50-4 5391
29
Doxepin Approved, Investigational Phase 4 1668-19-5 667477 667468
30
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
31
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
32
Testosterone enanthate Approved Phase 4 315-37-7 9416
33
Methyltestosterone Approved Phase 4 58-18-4 6010
34
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
35
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
36
Metronidazole Approved Phase 4 443-48-1 4173
37
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
38
Zoledronic Acid Approved Phase 4 118072-93-8 68740
39
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
40
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
41
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
42
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
43
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
44
carbamide peroxide Approved Phase 4 124-43-6
45
Lithium carbonate Approved Phase 4 554-13-2
46
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
47
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
48
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
49
Polyestradiol phosphate Approved Phase 4 28014-46-2
50
Ofloxacin Approved Phase 4 82419-36-1 4583

Interventional clinical trials:

(show top 50) (show all 4689)
# Name Status NCT ID Phase Drugs
1 Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism in ARV-naive HIV-infected Subjects Unknown status NCT00759070 Phase 4 Tenofovir + emtricitabine + efavirenz;Tenofovir + emtricitabine + lopinavir/ritonavir
2 Open Label Phase 4, 48 Week Pilot Study of the Antiviral Efficacy and Tolerability of the Combination of Isentress™ and ReyatazTM When Substituted for Current Antiviral Regimen in Patients With Viral Suppression But Who Are Experiencing Adverse Events Related to Their Current Antiviral Regimen. Unknown status NCT00751153 Phase 4 Raltegravir and Atazanavir
3 An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks Unknown status NCT00426296 Phase 4 atazanavir (Reyataz);ritonavir (Norvir)
4 Pilot, Open-label, Randomized, Single-center Study to Asses a Simplification Strategy From Protease Inhibitors to Raltegravir: Once Daily Isentress (ODIS) Unknown status NCT00941083 Phase 4 Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy)
5 Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine Unknown status NCT00564057 Phase 4 candesartan;lercanidipine
6 Study of the Immunogenicity and Immunological Memory Induced by the 13valent Pneumococcal Conjugate(PCV13) and 23valent Plain Polysaccharide Vaccine(PPV23) in HIV-infected Adults Unknown status NCT03041051 Phase 4
7 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
8 A Pilot Study of Highly Active Antiretroviral Therapy Using Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Antiretroviral Naive HIV-Infected Subjects Unknown status NCT00740064 Phase 4 Raltegravir and Abacavir/Lamivudine
9 Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy in Brazil: a "Real Life" Study Unknown status NCT01049685 Phase 4 First-line Antiretroviral Therapy
10 A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
11 MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) Unknown status NCT00122226 Phase 4 Lopinavir/ritonavir + zidovudine + lamivudine;Lopinavir/ritonavir + nevirapine
12 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection Unknown status NCT00885664 Phase 4 Truvada (tenofovir/emitricitabine);Kaletra (lopinavir/ritonavir)
13 A Phase IV, Open-Label, Randomized Study to Compare the Efficacy and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) for 96 Weeks in the Treatment of HIV-1 Infected Subjects Who Are Antiretroviral Therapy Naive Unknown status NCT00005017 Phase 4 Ritonavir;Abacavir sulfate;Amprenavir;Efavirenz;Lamivudine;Stavudine
14 Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients Receiving Protease Inhibitors: a Randomized, Prospective, Controlled Pilot Study. Unknown status NCT00843661 Phase 4 ezetimibe;fenofibrate;pravastatin
15 A Randomized, Open-Label, Study of Nelfinavir or Efavirenz in HIV-1 Infected, Antiretroviral Naive Patients Unknown status NCT00005000 Phase 4 Nelfinavir mesylate;Efavirenz;Lamivudine;Keyhole-Limpet Hemocyanin;Stavudine;Zidovudine;Didanosine
16 Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
17 Hepatic Safety of Raltegravir-based and Efavirenz-based Antiretroviral Regimens in Antiretroviral-Naïve HIV-infected Subjects Co-Infected With Hepatitis C Unknown status NCT01147107 Phase 4 Raltegravir;Efavirenz
18 Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach Unknown status NCT01875952 Phase 4 Isoniazid
19 Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in Patients With HIV. Influence on Morphological and Metabolic Disorders. A Randomized, Open-Label Multicenter Trial. Unknown status NCT00135460 Phase 4 nucleoside analogue sparing HAART regimen
20 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
21 A Randomized Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication Unknown status NCT00840762 Phase 4
22 A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
23 Pilot Study of the Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection Unknown status NCT01343225 Phase 4 atripla;darunavir ritonavir raltegravir
24 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4 cotrimoxazole;Placebo
25 Phase IV, Randomized, Open Label, Crossover, Intervention Trial to Investigate the Effect of the Switch of Lopinavir/Ritonavir to Raltegravir on Endothelial Function, Chronic Inflammation, Immune Activation and HIV Replication <50 Copies/ml Unknown status NCT01453933 Phase 4 raltegravir
26 SPNS Buprenorphine and Integrated HIV Care Evaluation and Support Center: Integration of Buprenorphine and HIV Treatment Using the OASIS Model Unknown status NCT00241930 Phase 4
27 Treating HIV-infected Elite Controllers as a Model of HIV Remission Unknown status NCT01025427 Phase 4 Raltegravir, tenofovir/emtricitabine
28 Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease Unknown status NCT00162643 Phase 4 zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
29 Efficacy of Pentoxyfylline Addition to a Treatment Scheme Based on Interferon Alpha and Ribavirin on Hepatitis C Virus Coinfected HIV Patients, Considering Interleukin 28B Polymorphism rs12979860 Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
30 The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial Unknown status NCT02401828 Phase 4 Dolutegravir
31 A Pilot Randomized, Open Label Study to Evaluate Efficacy and Safety of the Combination of RAL+ATV/r in Comparison With TDF/FTC+ATV/r in HIV Infected Patients, Who Failed an Initial NNRTI Containing Regimen Unknown status NCT01829802 Phase 4 Ritonavir boosted Atazanavir;Raltegravir;TDF/FTC (or 3TC)
32 Implementation of HIV Preexposure Prophylaxis With Antiretroviral Medications Among People at High Risk for HIV Infection: A Demonstration Project Unknown status NCT02206555 Phase 4 emtricitabine/tenofovir disoproxil fumarate
33 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
34 Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4 first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT);second line ARV therapy (3TC+TDF+LPV/RTV)
35 An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings Unknown status NCT00124358 Phase 4 Buprenorphine
36 Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens With Other PI's/NNRTI's in HIV+ Children and Adolescents With Elevated Lipid Levels Unknown status NCT00940771 Phase 4 Boosted Atazanavir
37 The Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection Unknown status NCT03205566 Phase 4 Raltegravir 400Mg Tab;Lamivudine 150Mg Tablet
38 A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
39 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
40 Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring Unknown status NCT00836212 Phase 4 Reducing dose of Lopinavir;Reducing dose of efavirenz
41 Pharmacokinetic Interaction Between Coartem® and Either Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4 Lumefantrine-artemether and nevirapine;lumefantrine-artemether and efavirenz;Lumefantrine-artemether and rifampicin
42 An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
43 1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection Unknown status NCT00885625 Phase 4
44 An Open-label Study in HIV+ Patients to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) Completed NCT02184078 Phase 4 Nevirapine;Rifabutin
45 A Pharmacokinetic Study to Assess Nevirapine Levels in HIV-infected Patients With Impaired Hepatic Function Completed NCT00144248 Phase 4 nevirapine
46 Adherence, Efficacy and Tolerance of Once-a-day Nevirapine-based Regimen in HIV-1 Infected Patients Completed NCT00466180 Phase 4
47 Efficacy and Safety of Switching From AZT to Tenofovir Completed NCT00647244 Phase 4 Tenofovir disoproxil fumarate;Abacavir
48 A Multicenter, Randomized, Open-label, Controlled Study of Nevirapine (VIRAMUNE®) and a Short Course of Prednisone to Determine the Safety and Effectiveness of This Strategy in Preventing Nevirapine (VIRAMUNE®) Associated Rash. Completed NCT02184299 Phase 4 Nevirapine;Prednisone
49 An Open-label Study in HIV+ Patients to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Fluconazole (DIFLUCAN®) Completed NCT02181946 Phase 4 Fluconazole;Nevirapine
50 Comparison of 2 Alternative Antiretroviral Combinations in HIV Post-exposure Prophylaxis: AZT-3TC (Combivir®) + Lopinavir-ritonavir (Kaletra®) Versus AZT-3TC (Combivir®)+ Atazanavir (Reyataz®). Multicentre, Prospective, Randomized, Open Study Completed NCT00385645 Phase 4 Combivir+Kaletra;Combivir+Reyataz

Search NIH Clinical Center for Human Immunodeficiency Virus Infectious Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Cobicistat
Emtricitabine
Lamivudine
Nevirapine
Ritonavir
Stavudine
Zidovudine

Genetic Tests for Human Immunodeficiency Virus Infectious Disease

Anatomical Context for Human Immunodeficiency Virus Infectious Disease

MalaCards organs/tissues related to Human Immunodeficiency Virus Infectious Disease:

41
Testes, T Cells, Liver, Bone, Endothelial, Monocytes, Brain

Publications for Human Immunodeficiency Virus Infectious Disease

Articles related to Human Immunodeficiency Virus Infectious Disease:

(show top 50) (show all 6298)
# Title Authors PMID Year
1
Rapid detection of HIV-1 p24 antigen using magnetic immuno-chromatography (MICT). 9 38
19482361 2009
2
Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. 9 38
19535523 2009
3
Expression and production of human interleukin-7 in insect cells using baculovirus expression vector system (BEVS). 9 38
18546077 2008
4
Emerging antiviral drugs. 9 38
18764719 2008
5
A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. 9 38
18096673 2008
6
A novel soluble mimic of the glycolipid, globotriaosyl ceramide inhibits HIV infection. 9 38
16439866 2006
7
Mycobacterium tuberculosis upregulates coreceptors CCR5 and CXCR4 while HIV modulates CD14 favoring concurrent infection. 9 38
16438645 2006
8
RNAi-directed inhibition of DC-SIGN by dendritic cells: prospects for HIV-1 therapy. 9 38
16353935 2005
9
Association of drug abuse with inhibition of HIV-1 immune responses: studies with long-term of HIV-1 non-progressors. 9 38
14741421 2004
10
Polymorphisms of CCR5 gene in a southern Chinese population and their effects on disease progression in HIV infections. 9 38
12461425 2002
11
Oral mucosal immunity and HIV infection: current status. 9 38
12164661 2002
12
Autoantibodies to TNFalpha in HIV-1 infection: prospects for anti-cytokine vaccine therapy. 9 38
11237281 2001
13
Correlation of virus load and soluble L-selectin, a marker of immune activation, in pediatric HIV-1 infection. 9 38
11101052 2000
14
Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4. 9 38
10195751 1999
15
[Early diagnosis of primary HIV infections: using a combined screening test (p24 antigen and anti-HIV antibodies)]. 9 38
10189669 1999
16
Heat shock protein-based therapeutic strategies against human immunodeficiency virus type 1 infection. 9 38
10231014 1999
17
Effect of zidovudine therapy in patients with HIV infection on endogenous interferon plasma levels and the hepatic cytochrome P450 enzyme system. 9 38
9612607 1998
18
New perspectives for the treatment of HIV infections. 9 38
9646721 1998
19
The role of biological response modifiers on apoptosis in HIV infections and AIDS. 9 38
17451286 1996
20
Solution conformation of an immunogenic peptide derived from the principal neutralizing determinant of the HIV-2 envelope glycoprotein gp125. 9 38
9079375 1996
21
Zinc and immune function. 9 38
7478075 1995
22
Differential effects of human immunodeficiency virus type 1 envelope protein gp120 on interferon production by mononuclear cells from adults and neonates. 9 38
7583919 1995
23
Immunologic marker paths for seroconversion: single determinations of immunoglobulin A and beta 2-microglobulin are not adequate to estimate time of HIV infection. Multicohort Analysis Project Workshop. Part II. 9 38
7946101 1994
24
[Interferon-gamma. Therapy of recurrent furunculosis in HIV infections]. 9 38
8104915 1993
25
Effectiveness of assays for antibodies to HIV and p24 antigen to detect very recent HIV infections in blood donors. The Retrovirus Study Group of the French Society of Blood Transfusion. 9 38
1492941 1992
26
The roles of apoptosis, autophagy and unfolded protein response in arbovirus, influenza virus, and HIV infections. 38
30966844 2019
27
Zimbabwean secondary school Guidance and Counseling teachers teaching sexuality education in the HIV and AIDS education curriculum. 38
31038004 2019
28
Antiretroviral Medications for the Prevention of HIV Infection: A Clinical Approach to Preexposure Prophylaxis, Postexposure Prophylaxis, and Treatment as Prevention. 38
31239092 2019
29
Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention. 38
31144296 2019
30
Strategies to promote the meaningful involvement of sex workers in HIV prevention and care. 38
31219886 2019
31
Evolving HIV epidemics: the urgent need to refocus on populations with risk. 38
31368909 2019
32
An initial randomized controlled trial of behavioral activation for treatment of concurrent crystal methamphetamine dependence and sexual risk for HIV acquisition among men who have sex with men. 38
30887824 2019
33
Safety and efficacy of Option B+ ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir/lamivudine/efavirenz. 38
31381233 2019
34
Investigating spatial disparities in high-risk women and HIV infections using generalized additive models: Results from a cohort of South African women. 38
31421797 2019
35
Estimates of the HIV undiagnosed population in Belgium reveals higher prevalence for MSM with foreign nationality and for geographic areas hosting big cities. 38
31424626 2019
36
Fifty Years in Search of Selective Antiviral Drugs. 38
30939009 2019
37
Prevalence of Alcohol Use and Factors Associated With Problem Drinking in Social Networks of People Living With HIV Infection in St. Petersburg, Russia. 38
31361515 2019
38
HIV risk and testing behaviors among pregnant women tested for HIV in Florida by site type, 2012. 38
30714499 2019
39
Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders. 38
31377844 2019
40
Updates on HIV nonoccupational postexposure prophylaxis. 38
30985387 2019
41
Prevalence of HIV Indeterminate Western Blot Tests and Follow-up of HIV Antibody Sero-Conversion in Southeastern China. 38
31190120 2019
42
The relationship between health-related variables and increases in smoking among recently diagnosed HIV+ people who inject drugs in Vietnam. 38
30903968 2019
43
Acceptability and Barriers to HIV Pre-Exposure Prophylaxis in Atlanta's Adolescents and Their Parents. 38
31436485 2019
44
Racial/Ethnic and HIV risk category disparities in PrEP discontinuation among patients in publicly-funded primary care clinics. 38
31436610 2019
45
Predictors of Disengagement in Care for Individuals Receiving Pre-exposure Prophylaxis (PrEP). 38
30985557 2019
46
Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA. 38
31402591 2019
47
Rapid elimination of broadly neutralizing antibodies correlates with treatment failure in the acute phase of SHIV infection. 38
31375583 2019
48
Simian-Human Immunodeficiency Virus SHIV.CH505-Infected Infant and Adult Rhesus Macaques Exhibit Similar Env-Specific Antibody Kinetics, despite Distinct T-Follicular Helper and Germinal Center B Cell Landscapes. 38
31092583 2019
49
Sex Worker Community-led Interventions Interrupt Sexually Transmitted Infection/Human Immunodeficiency Virus Transmission and Improve Human Immunodeficiency Virus Cascade Outcomes: A Program Review from South India. 38
31295225 2019
50
The current state of human immunodeficiency virus-associated lymphoma in Japan: a nationwide retrospective study of the Japanese Society of Hematology Blood Disease Registry. 38
31111394 2019

Variations for Human Immunodeficiency Virus Infectious Disease

Expression for Human Immunodeficiency Virus Infectious Disease

Search GEO for disease gene expression data for Human Immunodeficiency Virus Infectious Disease.

Pathways for Human Immunodeficiency Virus Infectious Disease

Pathways related to Human Immunodeficiency Virus Infectious Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.1 TNF IL7R IL7 IL2 IL10 IFNG
2
Show member pathways
13.93 TNF IL7R IL7 IL2 IL10 CXCR4
3
Show member pathways
13.74 TNF IL7R IL7 IL2 IL10 IFNG
4
Show member pathways
13.63 TNF IL7R IL7 IL2 IL10 IFNG
5
Show member pathways
13.51 TNF IL7R IL7 IL2 IL10 CXCR4
6
Show member pathways
13.42 TNF IL7R IL7 IL2 IL10 IFNG
7
Show member pathways
13.34 TNF IL7R IL7 IL2 IL10 CXCR4
8
Show member pathways
13.19 TNF IL2 IL10 IFNG IFNA1 CCL5
9
Show member pathways
13.08 TNF IFNA1 CXCR4 CXCL12 CD4 CCR5
10
Show member pathways
13.01 TNF IL2 IL10 IFNG IFNA1 CXCR4
11
Show member pathways
12.96 CXCR4 CXCL12 CD4 CCR5 CCL5 CCL4
12 12.92 IL7R IL7 IL2 IFNG IFNA1 CXCR4
13
Show member pathways
12.82 TNF IFNG IFNA1 CXCL12 CCL5 CCL4
14
Show member pathways
12.71 TNF IFNG CXCR4 CD4 CCR5
15
Show member pathways
12.71 TNF IL2 IL10 IFNG CD4 CD28
16
Show member pathways
12.71 TNF IL2 IL10 IFNG CD4 CD28
17
Show member pathways
12.69 TNF IL2 IL10 IFNG CD4 CD28
18
Show member pathways
12.63 TNF IL2 IL10 IFNG CD4
19
Show member pathways
12.5 IL7R IL7 IL2 IL10 IFNG IFNA1
20
Show member pathways
12.42 CXCR4 CXCL12 CCR5 CCL5 CCL4 CCL3
21
Show member pathways
12.36 TNF IL2 IL10 IFNG IFNA1 CXCL12
22
Show member pathways